- Report
- October 2024
- 187 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 193 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2024
- 135 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- January 2024
- 95 Pages
United States
€3327EUR$3,500USD£2,795GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
- Report
- March 2025
- 50 Pages
Global
From €2519EUR$2,650USD£2,116GBP
Ergotamine is a drug used to treat migraine headaches. It is a member of the class of drugs known as Central Nervous System (CNS) drugs, which are used to treat a variety of neurological conditions. Ergotamine works by constricting the blood vessels in the brain, reducing the pain associated with migraine headaches. It is usually taken orally, but can also be administered intravenously or intramuscularly.
Ergotamine is available in both prescription and over-the-counter forms. It is often used in combination with other medications, such as anti-nausea drugs, to provide relief from migraine headaches. Common side effects of ergotamine include nausea, vomiting, dizziness, and drowsiness.
The ergotamine market is highly competitive, with many companies offering different formulations of the drug. Some of the major players in the market include GlaxoSmithKline, Novartis, Pfizer, and Sanofi. Other companies that produce ergotamine include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more